Compare MBOT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBOT | IMUX |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 152.6M |
| IPO Year | 2000 | 2013 |
| Metric | MBOT | IMUX |
|---|---|---|
| Price | $1.73 | $14.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $7.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.6M | 253.5K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,887.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.51 |
| 52 Week High | $4.62 | $14.69 |
| Indicator | MBOT | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 33.23 | 80.68 |
| Support Level | $1.65 | $0.74 |
| Resistance Level | $2.23 | N/A |
| Average True Range (ATR) | 0.12 | 1.16 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 11.85 | 84.87 |
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.